Cisplatin Developers Join Forces

Such outcomes may be linked to the high rate of organ-confined disease in patients with high-risk PCa. According to several studies including ours, ?20�C30% of patients were pathologically downstaged to pT2 at the time of surgery [10, 11] Several limitations of the present study should be noted. First, the study period was long, ranging from 1990 to 2013 and, with only 523 patients, subgroup analysis based on years of surgery was not statistically achievable. Changes over time in http://www.selleckchem.com/products/3-methyladenine.html pathological assessment (Gleason score grading), patient selection and operating techniques, such as nerve-sparing procedures impacting the margin status, were sources of unavoidable bias. No centralised pathology was available between the two centres. Finally, because of missing key data required for the predictive tool, the final analysis only included 523 of the 814 patients identified. In conclusion, RP is playing an increasingly important role in the management of high-risk PCa. Our findings confirm that patients with preoperative high-risk PCa represent a heterogeneous group with high likelihood of specimen-confined disease and that RP offers good oncological outcomes. We externally validated the Briganti nomogram for the selection of patients with high-risk PCa with favourable pathology and thus, for whom RP offers the best chance of cure. Despite its relevant accuracy, based on the present multicentric cohort, this nomogram showed a lower accuracy for intermediate risk http://www.selleck.cn/products/Cisplatin.html disease. Improvements are required to aid treatment decision-making, for example, by adding new http://www.selleckchem.com/products/PD-0325901.html variables such as multiparametric MRI and biomarkers. Authors had no conflicts of interest. ""Study Type �C Therapy (case series) Level of Evidence?4 To report the heterogeneity in the treatment of patients with cT1 urothelial carcinoma by different surgeons, and to report outcomes in patients with and without bacillus Calmette-Gu��rin (BCG) treatment. We retrospectively reviewed 396 patients who had undergone a re-staging transurethral resection (TUR) for cT1 bladder cancer. We assessed both differences in the treatment by surgeon, and the association of early treatment with BCG with recurrence, progression and bladder cancer-specific death. Muscle was captured in the re-staging TUR specimen in a median of 76% of patients (range 50�C94 when stratified by surgeon). On multivariable analysis there was significant heterogeneity among surgeons in the use of early cystectomy (P